Palatin has a research program in DR, and more specifically, in diabetic macular edema (DME), a complication of DR that ...

The agreement with Palatin follows a $1bn deal with Re-Vana earlier this year as Boehringer targets the ophthalmology market.

Medically reviewed by Erika Prouty, PharmD While Ozempic (semaglutide) can help manage blood sugar in type 2 diabetes or ...

The NEW DAY study evaluating Iluvien for diabetic macular edema did not meet its primary endpoint, but showed favorable ...

New research has raised concerns that widely used weight-loss medications such as Ozempic, Wegovy, Mounjaro, and Zepbound may be associated with an increased risk of serious eye conditions, including ...

Comprehensive eye exams are vital for detecting early signs of systemic diseases like diabetes, hypertension, and high ...

Studies have linked GLP-1 medications to various eye conditions, some of which may lead to vision loss. Despite these ...

An observational study of 160,000 patients with diabetes taking GLP-1 drugs finds no heightened risk for retinopathy ...

Diabetic retinopathy and diabetic macular edema (DME) are two of the most common vision conditions related to diabetes. They affect about 1 in 4 people with type 1 and type 2 diabetes.

This phase 2b/3 trial follows new, positive 2-year data from the phase 2 ALTITUDE trial, in which sura-vec was well-tolerated ...

Diabetic retinopathy, a type of diabetic eye disease, is one of the leading causes of blindness in the United States. Despite this, almost 40% of people with diabetes don’t get an annual eye exam.

Diabetic retinopathy happens when elevated blood sugar levels cause damage to the blood vessels in the retina. The retina plays a crucial role in transmitting visual images to the brain.